14th December 2021
Celix Pharma is pleased to announce the grant of its Marketing Authorisation (MA) for Abiraterone 500mg Film-coated tablets by the MHRA.
Abiraterone is a hormonal therapy drug, used in conjunction with steroids, for the treatment of advanced prostate cancer. Prostate cancer needs the hormone testosterone to grow. Abiraterone works by reducing the amount of testosterone made by the body, thereby controlling the growth of prostate cancer (1).
Commenting on this approval, Subir Kohli, Co-founder & CEO says, “We are pleased with the approval of Abiraterone Tablets by the MHRA. This approval represents another key milestone for Celix, being the first of several products within our Oncology portfolio. We look forward to bringing this critical medicine to market upon expiry of the relevant data / marketing exclusivity of the reference product”.
Shantreddy, Co-founder & COO commented, “Abiraterone is special as we used a different regulatory pathway offered by the MHRA post-Brexit, something we are likely to use increasingly going forward”.
1. Source: Macmillan Cancer Support (https://www.macmillan.org.uk/)
About Celix Pharma Ltd
Celix Pharma is a London-based generic pharmaceutical company founded in 2020 with an overarching goal to bring high quality, affordable, generic medicines with a sustainable supply chain to the UK. Celix Pharma focuses on bridging gaps in the market by identifying product opportunities arising from complexities in development and/or manufacturing, addressing supply disruptions and future patent expiries with a portfolio spanning generics, value-added generics, and hospital specialty products. Celix Pharma’s business model is built around creating a commercially led, customer-focused organization supported with strategic partnerships in R&D and manufacturing.
For more information, visit www.celixpharma.com